BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gong Y, Huang ZB, Christensen E, Gluud C, Gong Y. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd000551.pub2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Selmi C, Torok NJ, Affronti A, Gershwin ME. Genomic variants associated with primary biliary cirrhosis. Genome Med 2010;2:5. [PMID: 20193050 DOI: 10.1186/gm126] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Lüth S, Weiler-Normann C, Schramm C, Lohse AW. [Autoimmune liver diseases]. Internist (Berl). 2009;50:310-317. [PMID: 19225747 DOI: 10.1007/s00108-008-2254-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable Rare Dis Res 2012;1:66-80. [PMID: 25343075 DOI: 10.5582/irdr.2012.v1.2.66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Djurisic S, Rath A, Gaber S, Garattini S, Bertele V, Ngwabyt SN, Hivert V, Neugebauer EAM, Laville M, Hiesmayr M, Demotes-Mainard J, Kubiak C, Jakobsen JC, Gluud C. Barriers to the conduct of randomised clinical trials within all disease areas. Trials 2017;18:360. [PMID: 28764809 DOI: 10.1186/s13063-017-2099-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
5 Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010;59:521-30. [PMID: 20332524 DOI: 10.1136/gut.2009.186528] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
6 Hirschfield GM, Al-Harthi N, Heathcote EJ. Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol. 2009;2:11-28. [PMID: 21180531 DOI: 10.1177/1756283x08098966] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
7 Terán A, Fábrega E, Pons-Romero F. [Pruritus associated with cholestasis]. Gastroenterol Hepatol 2010;33:313-22. [PMID: 19836105 DOI: 10.1016/j.gastrohep.2009.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Selmi C, Podda M. Methotrexate for primary biliary cirrhosis: who is to be trusted? Dig Dis Sci 2010;55:3013-5. [PMID: 20945095 DOI: 10.1007/s10620-010-1435-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009;31:283-307. [PMID: 19603170 DOI: 10.1007/s00281-009-0164-5] [Cited by in Crossref: 114] [Cited by in F6Publishing: 96] [Article Influence: 8.8] [Reference Citation Analysis]
10 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
11 Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med. 2017;32:213-228. [PMID: 28171717 DOI: 10.3904/kjim.2016.268] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
12 Drapkina OM, Bueverova EL. [Ursodeoxycholic acid: A therapeutic niche in an internist's practice]. Ter Arkh 2015;87:84-90. [PMID: 26087640 DOI: 10.17116/terarkh201587484-90] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Diesinger T, Buko V, Lautwein A, Dvorsky R, Belonovskaya E, Lukivskaya O, Naruta E, Kirko S, Andreev V, Buckert D, Bergler S, Renz C, Schneider E, Kuchenbauer F, Kumar M, Günes C, Büchele B, Simmet T, Müller-Enoch D, Wirth T, Haehner T. Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis. PLoS One 2020;15:e0235990. [PMID: 32701948 DOI: 10.1371/journal.pone.0235990] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjögren’s syndrome: autoimmune epithelitis. J Autoimmun. 2012;39:34-42. [PMID: 22178199 DOI: 10.1016/j.jaut.2011.11.005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 7.2] [Reference Citation Analysis]
15 Trivedi PJ, Hirschfield GM. Treatment of autoimmune liver disease: curr ent and future therapeutic options. Ther Adv Chronic Dis. 2013;4:119-141. [PMID: 23634279 DOI: 10.1177/2040622313478646] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
16 Zhu GQ, Shi KQ, Huang S, Huang GQ, Lin YQ, Zhou ZR, Braddock M, Chen YP, Zheng MH. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. Medicine (Baltimore) 2015;94:e609. [PMID: 25789951 DOI: 10.1097/MD.0000000000000609] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
17 Papastergiou V, Tsochatzis EA, Rodriguez-Peralvarez M, Thalassinos E, Pieri G, Manousou P, Germani G, Rigamonti C, Arvaniti V, Karatapanis S, Burroughs AK. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther 2013;38:1354-64. [PMID: 24117847 DOI: 10.1111/apt.12522] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
18 Tsochatzis EA, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, Burroughs AK. Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy. Biomed Res Int. 2013;2013:139763. [PMID: 23984317 DOI: 10.1155/2013/139763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
19 Liu Y, Tian S, Jia G, Han Z, Guo C, Shang Y, Han Y. Symptoms Burden and Health-related Quality of Life in Chinese Patients with Primary Biliary Cholangitis. J Clin Transl Hepatol 2021;9:860-7. [PMID: 34966649 DOI: 10.14218/JCTH.2020.00119] [Reference Citation Analysis]
20 Bhalerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol Res Pract 2015;2015:295891. [PMID: 25861254 DOI: 10.1155/2015/295891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
21 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551.pub3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
22 Ianiro G, Pecere S, Giorgio V, Gasbarrini A, Cammarota G. Digestive Enzyme Supplementation in Gastrointestinal Diseases. Curr Drug Metab 2016;17:187-93. [PMID: 26806042 DOI: 10.2174/138920021702160114150137] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
23 Zeniya M, Wada T. The therapeutic effect of UDCA is a factor in determining the prognosis of primary biliary cirrhosis. J Gastroenterol 2014;49:1438-9. [PMID: 24898105 DOI: 10.1007/s00535-014-0969-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Poropat G, Giljaca V, Stimac D, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2011;:CD003626. [PMID: 21249655 DOI: 10.1002/14651858.CD003626.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
25 Kotb MA. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012;13:8882-914. [PMID: 22942741 DOI: 10.3390/ijms13078882] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
26 Zhu GQ, Huang S, Huang GQ, Wang LR, Lin YQ, Wu YM, Shi KQ, Wang JT, Zhou ZR, Braddock M, Chen YP, Zhou MT, Zheng MH. Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. Oncotarget 2015;6:24533-49. [PMID: 26109432 DOI: 10.18632/oncotarget.4528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
27 Kotb MA. Ursodeoxycholic acid in neonatal hepatitis and infantile paucity of intrahepatic bile ducts: review of a historical cohort. Dig Dis Sci 2009;54:2231-41. [PMID: 19082720 DOI: 10.1007/s10620-008-0600-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
28 Tanaka T, Yamashiki N, Sugawara Y, Tamura S, Nakamura M, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N. Chronologic changes of explanted liver volume and the use of ursodeoxycholic acid in patients with end-stage primary biliary cirrhosis. Hepatol Res 2014;44:993-9. [PMID: 24298893 DOI: 10.1111/hepr.12283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]